Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

Medicaid expansion is associated with lower 2- and 4-year mortality among patients with resectable non-small cell lung cancer ...

Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ...

Yes, lung cancer can be curable — if it’s found early and responds well to treatment. Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus ...

Investing.com -- BeyondSpring Inc (NASDAQ:BYSI) shares gained 4.6% in premarket trading Friday following the company’s announcement of positive results from the Asian subset of its Phase 3 DUBLIN-3 ...

A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Median overall ...

When treated with KRAS inhibitors alone, cancer cells can escape destruction by using the salvage pathway to gather ...